EMEA
MCID: JVN026
MIFTS: 24

Jeavons Syndrome (EMEA)

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Jeavons Syndrome

MalaCards integrated aliases for Jeavons Syndrome:

Name: Jeavons Syndrome 58
Eyelid Myoclonia with and Without Absences 58
Emea 58

Characteristics:

Orphanet epidemiological data:

58
jeavons syndrome
Age of onset: Childhood;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 G40.3
Orphanet 58 ORPHA139431

Summaries for Jeavons Syndrome

MalaCards based summary : Jeavons Syndrome, also known as eyelid myoclonia with and without absences, is related to juvenile absence epilepsy and epilepsy. The drugs Thrombin and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and liver.

Wikipedia : 74 Jeavons syndrome is a type of epilepsy. It is one of the most distinctive reflex syndromes of idiopathic... more...

Related Diseases for Jeavons Syndrome

Graphical network of the top 20 diseases related to Jeavons Syndrome:



Diseases related to Jeavons Syndrome

Symptoms & Phenotypes for Jeavons Syndrome

Drugs & Therapeutics for Jeavons Syndrome

Drugs for Jeavons Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Ribavirin Approved Phase 4 36791-04-5 37542
3
Natalizumab Approved, Investigational Phase 4 189261-10-7
4
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
7
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
10
Lopinavir Approved Phase 4 192725-17-0 92727
11
Interferon beta-1b Approved Phase 4 145155-23-3
12
Nevirapine Approved Phase 4 129618-40-2 4463
13
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
14
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
15
Cinacalcet Approved Phase 4 226256-56-0 156419
16
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
17
Dabigatran Investigational Phase 4 211914-51-1
18 Anti-Infective Agents Phase 4
19 Vaccines Phase 4
20 Hemagglutinins Phase 4
21 Antithrombins Phase 4
22 Serine Proteinase Inhibitors Phase 4
23 Antithrombin III Phase 4
24 Anticoagulants Phase 4
25 Antiviral Agents Phase 4
26 interferons Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Analgesics Phase 4
29 Hormone Antagonists Phase 4
30 Hormones Phase 4
31 Antimetabolites Phase 4
32 Anti-Retroviral Agents Phase 4
33 Cyclooxygenase 2 Inhibitors Phase 4
34 Cyclooxygenase Inhibitors Phase 4
35 Antirheumatic Agents Phase 4
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4
37 Tissue Plasminogen Activator Phase 4
38 Adjuvants, Immunologic Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4
40 Anti-HIV Agents Phase 4
41 Iron-Dextran Complex Phase 4
42 Cytochrome P-450 CYP3A Inhibitors Phase 4
43 Interferon-beta Phase 4
44 Reverse Transcriptase Inhibitors Phase 4
45 Calcium, Dietary Phase 4
46
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
47
Calcium Nutraceutical Phase 4 7440-70-2 271
48
Pancrelipase Approved, Investigational Phase 3 53608-75-6
49
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
50
Rivaroxaban Approved Phase 3 366789-02-8

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations Completed NCT01306305 Phase 4
2 Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2009/2010-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations Completed NCT01306253 Phase 4
3 Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2008/2009-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations Completed NCT01303510 Phase 4
4 An Open Label, Non-comparative, Pharmacokinetic and Pharmacodynamic Study to Evaluate the Effect of Dabigatran Etexilate on Coagulation Parameters Including a Calibrated Thrombin Time Test in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Primary Unilateral Elective Total Knee or Hip Replacement Surgery Completed NCT01184989 Phase 4 Dabigatran etexilate
5 Open-label, Uncontrolled Postmarketing Study to Evaluate Immunogenicity, Safety and Tolerability of Cell-derived A/H1N1 Influenza HA Vaccine in Healthy Japanese Elderly Subjects Completed NCT01069367 Phase 4
6 Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study Completed NCT00942214 Phase 4 Natalizumab
7 Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's Completed NCT00447759 Phase 4 Celecoxib;Diclofenac
8 Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) in the Management of Patient With Acute Stroke Within 3-hour After Their Symptom Onset Who Are Admitted to a Remote Hospital With no Stroke Unit Facility Completed NCT00279149 Phase 4
9 A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent. Completed NCT00866021 Phase 4 Lopinavir/ritonavir;Lopinavir/ritonavir with two nucleoside analogs
10 De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
11 Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products. Completed NCT00455585 Phase 4 nevirapine, stavudine, lamivudine
12 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
13 APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long Term Safety Of Tacrolimus Ointment For The Treatment Of Atopic Dermatitis Withdrawn NCT00368719 Phase 4 Tacrolimus
14 Clopidogrel Proton-Pump Inhibitors Study Withdrawn NCT01016717 Phase 4 Omeprazole;Pantoprazole
15 Revaccination With Pneumococcal Conjugate Vaccine - Characterization Of The Immune Response After Polysaccharide Completed NCT00853749 Phase 3
16 A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Adult Subjects Completed NCT00996138 Phase 2, Phase 3
17 Single and Multiple Dose Trial to Evaluate Pharmacokinetics, -Dynamics and Safety of iv Paracetamol in Preterm and Term Neonates Completed NCT00969176 Phase 2, Phase 3 paracetamol
18 An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT01747330 Phase 3 Pancreatin
19 Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults Completed NCT00383539 Phase 3
20 Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly Completed NCT00383526 Phase 3
21 An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine Administered by Intradermal Route (Flu-ID 15μg) Versus an Inactivated Adjuvanted Influenza Vaccine Administered by Intramuscular Route in Subjects 65 Years of Age or Older Completed NCT00554333 Phase 3
22 A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis Completed NCT01059344 Phase 3 Mesalamin
23 A Phase III, Multicenter, Uncontrolled, Open Label Study to Evaluate Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects Completed NCT01161264 Phase 3
24 A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric Subjects Completed NCT01000207 Phase 2, Phase 3
25 Multicentric, Parallel, Controlled, Randomized, Single-blind Clinical Evaluation of New Low Sodium Peritoneal Dialysis Solution on Patients With Hypertension Treated With Continuous Ambulatory or Automated Peritoneal Dialysis Completed NCT00794326 Phase 3 Solution for Peritoneal Dialysis
26 A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation Completed NCT00434161 Phase 3 Palifermin before only;Placebo;Palifermin before and after
27 Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission Completed NCT02605720 Phase 3 Dihydroartemisinin-piperaquine
28 A Open-Label Study of the Transition to Rivaroxaban From Low-Molecular Weight Heparin for Venous Thromboembolism Prophylaxis After Total Joint Replacement: The Safe Simple Transitions Study Completed NCT01094886 Phase 3 Rivaroxaban
29 A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder Completed NCT00391222 Phase 3 Olanzapine;Placebo;Risperidone Long Acting Injectable (LAI)
30 A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Recruiting NCT03836014 Phase 3
31 TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome. Not yet recruiting NCT03357874 Phase 3 Clopidogrel;Ticagrelor
32 Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure Terminated NCT01076816 Phase 3 dexmedetomidine
33 Xenon-inhalation: Elimination of Xenon and Its Effect on Erythropoetin Levels in Blood of Healthy Volunteers Terminated NCT02129400 Phase 3 Xenon pro Anaesthesia 100 % (V/V);Aer medicinalis Linde 100%
34 Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial Unknown status NCT01728818 Phase 2 Gemcitabine;Afatinib;Gemcitabine
35 Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer Unknown status NCT01019798 Phase 2 sunitinib, docetaxel, cisplatin
36 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
37 Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly Completed NCT00415129 Phase 2
38 Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Children Aged 10 to Less Than 18 Years Completed NCT01035749 Phase 2
39 Immunogenicity Study of the Influenza Vaccine in Adults Completed NCT00258934 Phase 2
40 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
41 A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes Completed NCT01305135 Phase 1, Phase 2 azacitidine and idarubicin
42 Randomized, DB, Parallel Group, MC Study to Evaluate the Efficacy and Safety of Four Doses of Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depigoid Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma Completed NCT01144429 Phase 2
43 Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis Completed NCT01516203 Phase 2 AZD5847;Ethambutol, isoniazid, pyrazinamide, rifampin
44 Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive. Completed NCT01503983 Phase 2 Trastuzumab;Capecitabine;Oxaliplatin
45 Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study With P144 Topical Adminsitration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00781053 Phase 2 P144 cream
46 INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group Completed NCT02343406 Phase 2 Depatuxizumab mafodotin;Temozolomide;Lomustine
47 Phase II, Multicenter, Randomized, Double-blind, Intraindividually Placebo Controlled Clinical Trial, to Evaluate Efficacy and Safety of p144 Topical Administration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00574613 Phase 2 P144;placebo
48 Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 Vaccine and GlaxoSmithKline H1N1 Vaccine in Children 6 Months to 12 Years of Age Completed NCT00980850 Phase 2
49 Phase II Trial Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk (MDS) Myelodysplastic Syndrome Resistant or Relapsing After ESA Agents (LODEFI) Recruiting NCT03387475 Phase 2 Deferasirox
50 Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (EQol-MDS) Recruiting NCT02912208 Phase 2 Eltrombopag/Revolade

Search NIH Clinical Center for Jeavons Syndrome

Genetic Tests for Jeavons Syndrome

Anatomical Context for Jeavons Syndrome

MalaCards organs/tissues related to Jeavons Syndrome:

40
Eye, Testes, Liver, Skin, Brain, Colon, Kidney

Publications for Jeavons Syndrome

Articles related to Jeavons Syndrome:

(show all 35)
# Title Authors PMID Year
1
An Overview of the Electroencephalographic (EEG) Features of Epilepsy with Eyelid Myoclonia (Jeavons Syndrome). 61
32369428 2020
2
Idiopathic (genetic) generalized epilepsies with absences: clinical and electrographic characteristics and seizure outcome. 61
32504278 2020
3
Pitfalls in the diagnosis of Jeavons syndrome: a study of 32 cases and review of the literature. 61
32554361 2020
4
Responsive Neurostimulation of the Thalamus Improves Seizure Control in Idiopathic Generalized Epilepsy: A Case Report. 61
32023343 2020
5
Jeavons syndrome in a family with GLUT1-deficiency syndrome. 61
31352161 2019
6
Jeavons Syndrome: An Overlooked Epilepsy Syndrome. 61
30683501 2019
7
The electroclinical features of idiopathic generalized epilepsy patients presenting with fixation-off sensitivity. 61
30530446 2018
8
Prognosis of Juvenile myoclonic epilepsy with eye-closure sensitivity. 61
30248569 2018
9
Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. 61
30062784 2018
10
Jeavons Syndrome: Clinical Features and Response to Treatment. 61
30082241 2018
11
A case of de novo NAA10 mutation presenting with eyelid myoclonias (AKA Jeavons syndrome). 61
29957440 2018
12
Ongoing Photosensitivity in An Elderly Patient With Jeavons Sydrome. 61
29722743 2018
13
Crossing the lines between epilepsy syndromes: a myoclonic epilepsy variant with prominent eyelid myoclonia and atonic components. 61
29171397 2018
14
Clinical features and outcome of 6 new patients carrying de novo KCNB1 gene mutations. 61
29264397 2017
15
Prevalence of Pathogenic Copy Number Variation in Adults With Pediatric-Onset Epilepsy and Intellectual Disability. 61
28846756 2017
16
A prospective study of the modified Atkins diet for adults with idiopathic generalized epilepsy. 61
26588588 2015
17
Preliminary neurocognitive outcomes in Jeavons syndrome. 61
26492104 2015
18
Jeavons syndrome as an occipital cortex initiated generalized epilepsy: Further evidence from a patient with a photic-induced occipital seizure. 61
26552567 2015
19
[Jeavons syndrome: importance of differential diagnosis in epilepsy]. 61
24300557 2014
20
The visual system in eyelid myoclonia with absences. 61
25130932 2014
21
Levetiracetam as alternative treatment in Jeavons syndrome. 61
24798222 2014
22
Jeavons syndrome in China. 61
24495864 2014
23
[Antiepileptic drugs and seizure aggravation]. 61
25591652 2014
24
The hitchhiker's guide to the role of (transient) hypoglycemia in refractory seizures and epilepsy. 61
22759689 2012
25
[Clinical and electroencephalographic characteristics of Jeavons syndrome]. 61
22931943 2012
26
Jeavons syndrome existing as occipital cortex initiating generalized epilepsy. 61
21729035 2011
27
10-year outcome of childhood epilepsy in well-functioning children and adolescents. 61
21371918 2011
28
Oxcarbazepine induced worsening of seizures in Jeavons syndrome: lessons learnt from an interesting presentation. 61
21339665 2011
29
Benign myoclonic epilepsy of infancy evolving to Jeavons syndrome. 61
20691946 2010
30
[Does Jeavons syndrome exist? A report of a series of 10 cases]. 61
20473833 2010
31
Eyelid myoclonia with absences (Jeavons syndrome): a well-defined idiopathic generalized epilepsy syndrome or a spectrum of photosensitive conditions? 61
19469840 2009
32
Absence status epilepticus in monozygotic twins with Jeavons syndrome. 61
18782694 2008
33
A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). 61
18248445 2008
34
Unusual features in eyelid myoclonia with absences: a patient with mild mental retardation and background slowing on electroencephalography. 61
16446119 2006
35
Syndromes of idiopathic generalized epilepsies not recognized by the International League Against Epilepsy. 61
16302876 2005

Variations for Jeavons Syndrome

Expression for Jeavons Syndrome

Search GEO for disease gene expression data for Jeavons Syndrome.

Pathways for Jeavons Syndrome

GO Terms for Jeavons Syndrome

Sources for Jeavons Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....